Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes

Cited 24 time in scopus
Metadata Downloads
Title
Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes
Author(s)
M A Jang; Sang-Heon Lee; Namshin Kim; C S Ki
Bibliographic Citation
Genetics in Medicine, vol. 17, no. 12, pp. 1007-1011
Publication Year
2015
Abstract
Purpose:One of the biggest challenges of exome and genome sequencing in the era of genomic medicine is the identification and reporting of secondary findings. In this study we investigated the frequency and spectrum of actionable pathogenic secondary findings in Korean exomes.Methods:Data from 196 Korean exomes were screened for variants from a list of 56 genes recommended by the American College of Medical Genetics and Genomics (ACMG) for return of secondary findings. Identified variants were classified according to the evidence-based guidelines reached by a joint consensus of the ACMG and the Association for Molecular Pathology.Results:Among the 196 exomes, which were from 100 healthy controls and 96 patients with suspected genetic disorders, 11 variants in 13 individuals were found to be pathogenic or likely pathogenic. We estimated that the frequency of actionable pathogenic secondary findings was 7% for the control subjects (7/100) and 6% for the patients with disease (6/96). For one autosomal-recessive disease, four individuals exhibited either one pathogenic or one likely pathogenic variant of the MUTYH gene, leading to a carrier frequency of 2% (4/196).Conclusion:Secondary findings are not uncommon in Korean exomes.Genet Med 17 12, 1007-1011.
Keyword
exomeKoreansecondary findingvariant
ISSN
1098-3600
Publisher
Springer-Nature Pub Group
DOI
http://dx.doi.org/10.1038/gim.2015.26
Type
Article
Appears in Collections:
Division of Biomedical Research > Genome Editing Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.